JP2023548110A5 - - Google Patents

Info

Publication number
JP2023548110A5
JP2023548110A5 JP2023525978A JP2023525978A JP2023548110A5 JP 2023548110 A5 JP2023548110 A5 JP 2023548110A5 JP 2023525978 A JP2023525978 A JP 2023525978A JP 2023525978 A JP2023525978 A JP 2023525978A JP 2023548110 A5 JP2023548110 A5 JP 2023548110A5
Authority
JP
Japan
Prior art keywords
ovarian cancer
n3ap
das
diacspmd
acspmd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023525978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548110A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/056852 external-priority patent/WO2022093960A1/en
Publication of JP2023548110A publication Critical patent/JP2023548110A/ja
Publication of JP2023548110A5 publication Critical patent/JP2023548110A5/ja
Pending legal-status Critical Current

Links

JP2023525978A 2020-10-29 2021-10-27 卵巣がんの検出及び治療方法 Pending JP2023548110A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063107160P 2020-10-29 2020-10-29
US63/107,160 2020-10-29
PCT/US2021/056852 WO2022093960A1 (en) 2020-10-29 2021-10-27 Methods for the detection and treatment of ovarian cancer

Publications (2)

Publication Number Publication Date
JP2023548110A JP2023548110A (ja) 2023-11-15
JP2023548110A5 true JP2023548110A5 (enExample) 2024-10-28

Family

ID=81383153

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023525978A Pending JP2023548110A (ja) 2020-10-29 2021-10-27 卵巣がんの検出及び治療方法

Country Status (7)

Country Link
US (1) US20240044902A1 (enExample)
EP (1) EP4237090B1 (enExample)
JP (1) JP2023548110A (enExample)
KR (1) KR20230113742A (enExample)
CN (1) CN116490776A (enExample)
CA (1) CA3196725A1 (enExample)
WO (1) WO2022093960A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024020427A2 (en) * 2022-07-21 2024-01-25 Board Of Regents, The University Of Texas System Methods for the detection and treatment of ovarian cancer
KR20250017689A (ko) 2023-07-27 2025-02-04 가톨릭대학교 산학협력단 난소암 발병 위험률 예측 방법 및 분석장치

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1610127B1 (en) * 2003-03-11 2012-04-25 CRC Inc. N1,n12-diacetylspermine as tumor marker
CA2535805A1 (en) * 2003-08-15 2005-02-24 University Of Pittsburgh Of The Commnonwealth System Of Higher Education Multifactorial assay for cancer detection
MX2009000452A (es) * 2006-07-14 2011-11-07 Mannkind Corp Metodos para producir, mejorar y sostener respuestas inmunes contra epitopos restringidos mhc clase i para propositos profilacticos o terapeuticos.
CN101855553B (zh) * 2007-06-29 2014-06-11 韩国安国药品株式会社 卵巢癌的预测标记
US9733256B2 (en) * 2012-02-23 2017-08-15 Keio University Combined anticancer drug sensitivity-determining marker
WO2013188391A2 (en) * 2012-06-11 2013-12-19 Georgia Regents University Biomarkers for ovarian cancer
GB201316347D0 (en) * 2013-09-13 2013-10-30 Cancer Rec Tech Ltd Biological fluid filtration assembly
US20160282351A1 (en) * 2013-10-28 2016-09-29 Salivatech Co., Ltd. Salivary biomarkers for cancers, methods and devices for assaying the same, and methods for determining salivary biomarkers for cancers
US10377783B2 (en) * 2015-06-12 2019-08-13 Brock University Methods and compounds for enhancing contrast in magnetic resonance imaging (MRI)
TW201800408A (zh) * 2016-06-15 2018-01-01 拜耳製藥公司 Mps-1抑制劑
FI3478286T3 (fi) * 2016-06-29 2024-03-14 Tesaro Inc Menetelmiä munasarjasyövän hoitamiseksi
KR102630885B1 (ko) * 2017-02-09 2024-01-29 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 폐암의 검출 및 치료 방법
WO2019178216A1 (en) * 2018-03-13 2019-09-19 Baylor Research Institute Methods and compositions for treating, diagnosing, and prognosing ovarian cancer
JP7272627B2 (ja) * 2019-01-24 2023-05-12 公立大学法人和歌山県立医科大学 卵巣腫瘍の評価用バイオマーカー
CN109870579B (zh) * 2019-02-03 2022-02-11 辽宁迈迪生物科技股份有限公司 单克隆抗体保护液及制备方法和应用、应用单克隆抗体保护液的试剂与免疫组化试剂盒

Similar Documents

Publication Publication Date Title
CN112011616B (zh) 预测肝细胞癌肿瘤免疫浸润和术后生存时间的免疫基因预后模型
Zinkin et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease
Bird–Lieberman et al. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus
Lee et al. Saliva: an emerging biofluid for early detection of diseases
JP2020510816A5 (enExample)
Zhang et al. Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient
JP2011505143A5 (enExample)
Lokeshwar et al. Urinary bladder tumor markers
Mueller et al. ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients
RU2014150777A (ru) Способ индикации наличия или отсутствия рака предстательной железы
US20250199007A1 (en) Extracellular vesicle biomarkers for bladder cancer
JP7179356B2 (ja) 代謝物分析を利用したベーチェット病の診断方法
US20240044902A1 (en) Methods for the detection and treatment of ovarian cancer
WO2024107923A1 (en) Methods for the detection and treatment of lung cancer
Yilmaz Serum proteomics for biomarker discovery in nonalcoholic fatty liver disease
EP4004549A1 (en) Progression markers for colorectal adenomas
Yildirim et al. Exploring the protein signature of endometrial cancer: A comprehensive review through diverse samples and mass spectrometry-based proteomics
CN120210363A (zh) 用于诊断晚期鼻咽癌的生物标志物及其应用
CN114217063A (zh) Fbln1和ctsf联合在诊断非小细胞肺癌脑转移中的应用
Henkel et al. From proteomic multimarker profiling to interesting proteins: thymosin‐β4 and kininogen‐1 as new potential biomarkers for inflammatory hepatic lesions
KR20250039409A (ko) 난소암의 검출 및 치료를 위한 방법
KR101859812B1 (ko) 간암 화학 색전술 치료 예후 예측을 위한 바이오마커 및 그 용도
CN110780070B (zh) 一种用于检测癌症化疗敏感性的血浆蛋白分子、应用及试剂盒
KR20240004546A (ko) 결장직장암에 대한 바이오마커
WO2022051818A1 (en) Marker associated with colorectal cancer